,datetime,sentence,positive,negative,neutral,global_sentiment,avg_sentiment
0,2018-10-19 07:01:00,"Chicago, IL -October 19, 2018 - Zacks.com announces the list of stocks featured in the Analyst Blog.",0.01830788142979145,0.008681373670697212,0.973010778427124,neutral,0.009626507759094238
1,2018-10-19 07:01:00,Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets.,0.021041298285126686,0.011407552286982536,0.9675511121749878,neutral,0.00963374599814415
2,2018-10-19 07:01:00,"Stocks recently featured in the blog include: AstraZenecaAZN , salesforce.comCRM , MastercardMA , Lam ResearchLRCX and Koninklijke PhilipsPHG .",0.02292902208864689,0.009886429645121098,0.9671845436096191,neutral,0.013042592443525791
3,2018-10-19 07:01:00,"Here are highlights from Thursday's Analyst Blog:

The Zacks Research Daily presents the best research output of our analyst team.",0.2266942709684372,0.009645335376262665,0.7636604309082031,neutral,0.21704894304275513
4,2018-10-19 07:01:00,"Today's Research Daily features new research reports on 12 major stocks, including AstraZeneca, salesforce.com and Mastercard.",0.04197313264012337,0.008782412856817245,0.9492444396018982,neutral,0.03319071978330612
5,2018-10-19 07:01:00,These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.,0.054846275597810745,0.007339245639741421,0.937814474105835,neutral,0.04750702902674675
6,2018-10-19 07:01:00,"AstraZeneca 's shares have gained +8% year to date, outperforming the Zacks Large Cap Pharmaceuticals industry which has gained +3.2% over the same period.",0.9579058885574341,0.023367425426840782,0.018726665526628494,positive,0.9345384836196899
7,2018-10-19 07:01:00,"AstraZeneca's newer drugs like Lynparza, Tagrisso and Brilinta should keep contributing to the top line while several launches are underway across each of the therapeutic areas, Oncology, CV metabolism and Respiratory.",0.6471381187438965,0.011615416966378689,0.34124645590782166,positive,0.635522723197937
8,2018-10-19 07:01:00,"Meanwhile, cost-cutting initiatives should drive the bottom line.",0.789933979511261,0.01989092119038105,0.1901751458644867,positive,0.7700430750846863
9,2018-10-19 07:01:00,AstraZeneca also has a promising late-stage pipeline that includes immuno-oncology candidates.,0.7604093551635742,0.01021086797118187,0.2293797880411148,positive,0.750198483467102
10,2018-10-19 07:01:00,Imfinzi is a key drug in the pipeline.,0.5964526534080505,0.011978847905993462,0.39156854152679443,positive,0.5844737887382507
11,2018-10-19 07:01:00,The company has a positive record of earnings surprises in the recent quarters.,0.9466361999511719,0.02157570794224739,0.03178815543651581,positive,0.925060510635376
12,2018-10-19 07:01:00,Estimates have remained stable ahead of the company's Q3 earnings release.,0.6195075511932373,0.030395733192563057,0.3500966727733612,positive,0.5891118049621582
13,2018-10-19 07:01:00,"Nevertheless, AstraZeneca's core products like Nexium, Crestor and Seroquel are facing generic competition, which is hurting sales growth.",0.019953632727265358,0.9659141302108765,0.014132155105471611,negative,-0.945960521697998
14,2018-10-19 07:01:00,The diabetes franchise also faces stiff competition while pricing pressure is hurting sales in the Respiratory franchise.,0.019698699936270714,0.9649874567985535,0.015313823707401752,negative,-0.9452887773513794
15,2018-10-19 07:01:00,"Strong Buy-rated Salesforce 's shares have gained +38.9% so far this year, handily outperforming the Zacks Computer - Software industry which gained +19% over the same period.",0.9558688998222351,0.025128671899437904,0.019002359360456467,positive,0.930740237236023
16,2018-10-19 07:01:00,Salesforce's diverse cloud offerings and strong spending on digital marketing remain the catalysts.,0.8468379378318787,0.011960097588598728,0.14120198786258698,positive,0.8348778486251831
17,2018-10-19 07:01:00,Management is extremely optimistic about enhancement of customer experience that has aided growth of the cloud segment.,0.9219916462898254,0.012629857286810875,0.06537846475839615,positive,0.9093617796897888
18,2018-10-19 07:01:00,"Additionally, strategic acquisitions and the resultant synergies are anticipated to prove conducive to growth over the long run.",0.9254710078239441,0.013231851160526276,0.0612972192466259,positive,0.912239134311676
19,2018-10-19 07:01:00,"Furthermore, the company's move of utilizing other data center operators like Amazon and Alphabet's geographical reach to expand its international business is commendable and will help it in achieving its targeted $23 billion sales mark by 2022.",0.9440549612045288,0.01475099939852953,0.04119410738348961,positive,0.9293039441108704
20,2018-10-19 07:01:00,"However, stiff competition, currency fluctuations and an increase in investments for international expansions and data centers could negatively impact near-term profitability.",0.02900855615735054,0.9142323136329651,0.056759193539619446,negative,-0.8852237462997437
21,2018-10-19 07:01:00,"Shares of Mastercard have increased +37.3% over the past year, significantly outperforming the Zacks Financial Transaction Services industry's rally of +22.2%.",0.9597451090812683,0.02216029353439808,0.018094610422849655,positive,0.9375848174095154
22,2018-10-19 07:01:00,"The company is poised for growth, given its solid market position, ongoing expansion and digital initiatives plus significant opportunities from the secular shift toward electronic payments.",0.9140021800994873,0.013170740567147732,0.07282701134681702,positive,0.9008314609527588
23,2018-10-19 07:01:00,"The buyouts of VocaLink and NuData Security complement efforts to participate in new payment flows, and enhance safety and security offerings.",0.9405254125595093,0.014455839060246944,0.045018672943115234,positive,0.9260695576667786
24,2018-10-19 07:01:00,The company has seen the Zacks Consensus Estimate for 2018 earnings being revised upward over the last 60 days.,0.747044026851654,0.06400098651647568,0.18895508348941803,positive,0.6830430626869202
25,2018-10-19 07:01:00,"However, escalating costs, higher incentives and rewards will put pressure on its bottom line.",0.5054378509521484,0.34674695134162903,0.14781519770622253,positive,0.1586908996105194
26,2018-10-19 07:01:00,Other noteworthy reports we are featuring today include Lam Research and Koninklijke Philips.,0.027958009392023087,0.005903436802327633,0.9661385416984558,neutral,0.02205457165837288
27,2018-10-19 07:01:00,Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time.,0.814492404460907,0.0160694383084774,0.1694381833076477,positive,0.7984229922294617
28,2018-10-19 07:01:00,It's a once-in-a-generation opportunity to invest in pure genius.,0.5448517799377441,0.011377338320016861,0.4437708854675293,positive,0.5334744453430176
29,2018-10-19 07:01:00,Past performance is no guarantee of future results.,0.023727279156446457,0.008731111884117126,0.9675416350364685,neutral,0.01499616727232933
30,2018-10-19 07:01:00,Inherent in any investment is the potential for loss .,0.023265572264790535,0.09617827832698822,0.8805561661720276,neutral,-0.07291270792484283
31,2018-10-19 07:01:00,"This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security.",0.011962415650486946,0.010706594213843346,0.9773310422897339,neutral,0.0012558214366436005
32,2018-10-19 07:01:00,No recommendation or advice is being given as to whether any investment is suitable for a particular investor.,0.01822577603161335,0.008984367363154888,0.9727898240089417,neutral,0.009241408668458462
33,2018-10-19 07:01:00,"It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable.",0.020858757197856903,0.007662615738809109,0.9714785814285278,neutral,0.013196141459047794
34,2018-10-19 07:01:00,All information is current as of the date of herein and is subject to change without notice.,0.01124907098710537,0.013303965330123901,0.9754469990730286,neutral,-0.002054894343018532
35,2018-10-19 07:01:00,Any views or opinions expressed may not reflect those of the firm as a whole.,0.008276145905256271,0.021656149998307228,0.9700676798820496,neutral,-0.013380004093050957
36,2018-10-19 07:01:00,"Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities.",0.009504852816462517,0.012596068903803825,0.9778990745544434,neutral,-0.0030912160873413086
37,2018-10-19 07:01:00,These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs.,0.14585068821907043,0.02033580094575882,0.8338135480880737,neutral,0.1255148947238922
38,2018-10-19 07:01:00,These are not the returns of actual portfolios of stocks.,0.010538044385612011,0.012450686655938625,0.9770112633705139,neutral,-0.0019126422703266144
39,2018-10-19 07:01:00,The S&P 500 is an unmanaged index.,0.022511588409543037,0.0801919475197792,0.8972964882850647,neutral,-0.05768036097288132
40,2018-10-19 07:01:00,Visit http://www.zacks.com/performance for information about the performance numbers displayed in this press release.,0.01104306522756815,0.014137434773147106,0.9748194813728333,neutral,-0.0030943695455789566
41,2018-10-19 07:01:00,Want the latest recommendations from Zacks Investment Research?,0.03539300337433815,0.011573811061680317,0.9530332088470459,neutral,0.023819193243980408
42,2018-10-19 07:01:00,"Today, you can download 7 Best Stocks for the Next 30 Days.",0.05069372057914734,0.007019792217761278,0.9422864317893982,neutral,0.04367392882704735
43,2018-10-19 07:01:00,"Click to get this free report

To read this article on Zacks.com click here.",0.020684564486145973,0.03315984085202217,0.9461556077003479,neutral,-0.012475276365876198
44,2018-10-19 07:01:00,"The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.",0.010204561054706573,0.01563790813088417,0.9741575717926025,neutral,-0.005433347076177597
